Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Advanced Solid Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Vanderbilt Universtiy Medical Center, Nashville, Tennessee, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

18 years of age or older
Advanced and/or metastatic solid tumor for which no effective therapy is available
ECOG performance status 0-2
Adequate bone marrow, hepatic and renal function

Exclusion criteria

Patients with active or uncontrolled infections
Neurotoxicity >= Grade 2
Symptomatic brain metastases which are not stable

Treatment and study plan

OSI-7904L

Drug

Cisplatin

Drug

Sponsors and collaborators

Lead sponsor

OSI Pharmaceuticals

Industry

Registry information

Official study title

Phase I Study of OSI-7904L in Combination With Cisplatin in Patients With Advanced Solid Tumors

Important dates

Study start: 2003
Study completion: 2004
First posted: Jul 1, 2005
Registry last updated: Jan 21, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed